Princeton Biopartners, a leading consultancy in Integrated Evidence Generation Planning and Medical Affairs strategy, has officially announced the launch of EVEXA®, which happens to be a groundbreaking platform, geared towards leveraging AI-driven agents to transform how pharmaceutical and biotech teams plan, execute, and measure evidence generation.
According to certain reports, the stated platform arrives bearing an ability to convert traditional, static Integrated Evidence Generation Plans (IEGPs) into living, data-connected strategy environments, capable of enabling Medical Affairs, Real-World Evidence (RWE), and Market Access teams to plan, adapt, and track in real time.
To understand the significance of such a development, we must take into account how, with pharma pipelines expanding and real-world data ecosystems becoming increasingly fragmented, evidence generation is now one of the industry’s most persistent challenges, with critical gaps already appearing across strategy design, execution, and impact measurement.
Against that, EVEXA® effectively combines Princeton Biopartners’ proprietary IEGP frameworks with advanced AI orchestration to achieve a single, intelligent workspace, designed to unify evidence planning across global, regional, and functional teams.
“We’re entering a new era where the lines between consulting, AI, and pharma execution are rapidly converging, and EVEXA® sits at that intersection,” said Rishabh Sethia, Investor at the Abu Dhabi Investment Fund. “Through the use of AI, the market is clearly shifting toward integrated strategy and technology solutions. Princeton’s model, combining deep therapeutic expertise with a powerful, real-time platform, is what the next generation of pharma execution will look like.”
Talk about the whole value proposition on a slightly deeper level, we begin from the promise of anchoring gap assessments in strategy. This translates to how EVEXA® links every evidence gap to a specific label claim or value pillar, something it does for the purpose of ensuring activities map directly to strategic intent.
Next up, there is a focus on integrating with the Clinical Development Plan (CDP). You see, the underlying platform can seamlessly synchronize Medical Affairs and R&D planning, thus helping teams identify which studies shape the label and which build post-launch value. Not just that, it also resolves the divide between regulatory and market strategy.
“EVEXA® is the AI agent that powers evidence strategy, continuously interpreting data to guide smarter, faster decisions,” said Dillon Shokar, Founder and Growth Lead at Princeton Biopartners. “It’s the intelligence layer shaping how pharma will compete and create value in the decade ahead.”
Another detail worth a mention is rooted in the potential for simplifying frameworks and realizing role clarity. In essence, EVEXA® replaces traditional “laundry lists” of studies with a prioritization engine which, on its part, distinguishes high-value evidence from noise, clarifies shared and distinct ownership between R&D and Medical Affairs, as well as aligns teams around the studies that truly move the needle.
Among other things, it ought to be acknowledged how the platform in question is already deployed across multiple top-50 biopharma organizations, As for the results, they include upto 40% faster evidence-plan refresh cycles, 2× improvement in cross-functional alignment scores, along with accelerated launch readiness for complex assets, including a recent rare disease program integrating U.S. and EU teams.
“EVEXA directly solves the real challenges Medical Affairs teams face every day, including fragmented evidence generation planning, static disconnected documents, and limited cross-functional visibility,” said Rogelio Braceras, who has held Medical Affairs leadership roles at Pfizer, Boehringer Ingelheim, Sanofi, and Jazz Pharmaceuticals. “What Princeton has built is not just another tool, it is a purpose-built solution that mirrors how Medical Affairs and Clinical Development actually work. The ability to track changes, align stakeholders, and identify strategic gaps in real time fundamentally transforms how we approach evidence generation planning, driving smarter, faster, and more integrated decisions.”
